BIOS Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Neural interface company developing closed-loop bioelectronic medicine devices; decodes peripheral nerve signals to treat diabetes, hypertension, and inflammatory conditions.
About
BIOS Health is a neural interface and closed-loop neuromodulation company developing bioelectronic medicine devices for treating chronic conditions. Founded in 2017 as a spinout from Cambridge University, BIOS Health builds implantable devices and software platforms that decode peripheral nerve signals to restore physiological function in patients with conditions including diabetes, hypertension, and inflammatory diseases. The company's approach combines machine learning with neural signal processing to enable real-time, adaptive therapy.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.